Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for HIND.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 -0.9037M
March 31, 2026 -1.436M
December 31, 2025 -1.478M
September 30, 2025 4.342M
June 30, 2025 -0.3063M
March 31, 2025 -0.2035M
December 31, 2024 -0.003M
September 30, 2024 2.818M
June 30, 2024 -1.357M
March 31, 2024 -2.072M
December 31, 2023 -2.457M
September 30, 2023 -2.78M
June 30, 2023 -6.662M
March 31, 2023 -5.061M
December 31, 2022 -2.829M
September 30, 2022 -5.273M
June 30, 2022 -6.422M
March 31, 2022 -7.378M
December 31, 2021 -3.426M
September 30, 2021 -7.80M
Date Value
June 30, 2021 -2.188M
March 31, 2021 -1.961M
December 31, 2020 -1.762M
September 30, 2020 -0.976M
June 30, 2020 -0.998M
March 31, 2020 -4.814M
December 31, 2019 -4.879M
September 30, 2019 -3.989M
June 30, 2019 -4.356M
March 31, 2019 -9.642M
December 31, 2018 -5.415M
September 30, 2018 -5.293M
June 30, 2018 -8.122M
March 31, 2018 -10.60M
December 31, 2017 -9.197M
September 30, 2017 -7.019M
June 30, 2017 -6.055M
March 31, 2017 -8.353M
December 31, 2016 -5.775M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Cardiac Biotech Solutions, Inc. -0.1918M
Anika Therapeutics, Inc. -0.684M
Enovis Corp. 75.03M
Edwards Lifesciences Corp. 651.90M
Perspective Therapeutics, Inc. -20.65M